Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)±folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients

M. A. Bensmane, A. De Gramont, S. Brienza, M. Marty, F. Lévi, M. Ducreux, E. François, E. Gamelin, H. Bleiberg, P. Bleuzen, J. Simon, E. Cvitkovic

    Research output: Contribution to journalArticlepeer-review

    7 Citations (Scopus)

    Abstract

    Univariate and multivariate analyses were performed on data from 370 5-fluorouracil (5-FU)-resistant advanced colorectal cancer patients treated with oxaliplatin (Eloxatin®)/5-FU±folinic acid (FA) to identify prognostic factors for oxaliplatin-based treatment. The response rate was 14.6% (95% confidence interval (CI): 11.0-18.2%), median time to progression was 4.3 months (95% CI: 3.9-4.7), and median overall survival 9.7 months (95% CI: 8.5-10.8). Multivariate analysis indicated < 2 prior chemotherapy regimens, bi-weekly treatment administration schedule (versus tri-weekly) and continuous chronomodulated delivery (CCM) as significantly associated (P < 0.05) with a higher overall response rate. Performance status (PS) < 2, having only one involved organ, biweekly schedule and CCM were associated (P < 0.05) with a longer time to progression. Good PS, one involved organ, low alkaline phosphatase (AP) serum levels, bi-weekly schedule and CCM were significantly correlated with longer overall survival, while confirming the efficacy of oxaliplatin/5-FU±FA in this indication. (C) 2000 Elsevier Science Ltd.

    Original languageEnglish
    Pages (from-to)2335-2343
    Number of pages9
    JournalEuropean Journal of Cancer
    Volume36
    Issue number18
    DOIs
    Publication statusPublished - 5 Dec 2000

    Keywords

    • Clinical resistance
    • Multivariate analysis
    • Salvage chemotherapy

    Cite this